Table 4.
Multivariable analysis of association with clinical outcomes to VEGFR-TKI after PD-1
| Variable | Objective response |
Progression-free survival |
||
|---|---|---|---|---|
| OR (95% CI) | P-value | RR (95% CI) | P-value | |
| IL-2 | ||||
| Yes versus no | 0.51 (0.09–2.79) | 0.437 | 1.10 (0.55–2.21) | 0.781 |
| Number of prior antiangiogenic therapies | ||||
| ≥1 versus 0 | 0.44 (0.11–1.70) | 0.233 | 1.19 (0.48–0.95) | 0.714 |
| MSKCC's criteria | ||||
| Good versus poor | 1.69 (0.28–10.1) | 0.391 | 0.71 (0.30–1.68) | 0.437 |
| Intermediate versus poor | 0.73 (0.15–3.63) | 0.419 | 0.62 (0.31–1.26) | 0.191 |
| Good versus intermediate | 2.31 (0.42–12.7) | 0.381 | 1.14 (0.49–2.64) | 0.757 |
| Time from the end of PD-1 therapy to subsequent VEGFR-TKI therapy | 0.50 (0.27–0.94) | 0.030 | 0.95 (0.85–1.06) | 0.365 |
| Type of PD-1 inhibitor regimen | ||||
| Immune checkpoint inhibitors alone versus PD-1 combined with VEGFR-TKI therapy | 5.83 (1.04–32.7) | 0.045 | 0.62 (0.29–1.32) | 0.218 |
Values in bold are statistically significant.
PD-1: programmed cell death 1; VEGFR-TKI: vascular endothelial growth factor receptor–tyrosine kinase inhibitors.